Contract service executives operate in a maturing industry where they must consistently deliver above-average performance. In this challenging environment of intense competition and expectations, an executive’s need for reliable, timely and in-depth market intelligence is critical for success. PharmSource delivers that intelligence.
Dose CMOs by the Numbers:
Composition, Size, Market Share and Outlook
This proprietary report is based on PharmSource’s expert quantitative analysis of the contract dose manufacturing market. It will help you understand the events behind both organic and inorganic revenue changes.
PharmSource’s experts explain the relative market shares of solid, semi-solid/liquid/injectable and specialty dose forms. Learn how industry revenues are distributed among bio/pharmaceutical Contract Manufacturing Organizations (CMOs) by size, and…
Territory Watch: Look Beyond the Usual to Capture New Business
The majority of bio/pharma funding events in the U.S. during 2014 and 2015 occurred outside the high-profile hubs of the San Francisco Bay Area and Boston. However, contract research organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) looking to capture new business will find…
Capturing CRO Opportunities in the Medical Device and Diagnostic Market
Contract research organizations (CROs) seeking to capture business in the medical device and diagnostic segment face a unique range of challenges, most prominently the lack of information shared by medical device companies during the development process. This white paper provides insights into how to overcome the obstacles and…
How big is the market for…?
We’ve developed a resource page that addresses questions about the size of the market for various segments of the bio/pharma contract services industry.
Bookmark the page at this link and check back often to stay up-to-date on how the bio/pharmaceutical contract services market is evolving.
Bio/Pharmaceutical Outsourcing Report:
NDA Outsourcing Up, Despite NME Decline
In what proved to be a mediocre year for drug approvals, the increase in outsourcing levels was restricted to the manufacture of non-new molecular entities (NMEs), which stood at 64%. In contrast, just under half of all NMEs were…